<?xml version="1.0" encoding="UTF-8"?>
<p>South Africa's National Action Plan 2017‐2021 is one of the first examples of an investment case that combines tools for costing, impact modelling, cost‐effectiveness analysis, and fiscal space analysis for scaled‐up hepatitis B and hepatitis C disease control scenarios.
 <xref rid="liv14222-bib-0035" ref-type="ref">35</xref> The action plan was developed in collaboration with leading South African experts, Ministry of Health officials, and external specialists in global health policy and economics, who assessed cost and affordability, health impact and cost‐effectiveness for four priority interventions: hepatitis B birth dose vaccination, prevention of MTCT and treatment for hepatitis B and C.
</p>
